Axsome Therapeutics, a biopharma company focused on central nervous system (CNS) disorders, reported robust growth for its three commercial products: AUVELITY (for major depressive disorder and Alzheimer's agitation), SYMBRAVO (for migraine), and SUNOSI (for excessive daytime sleepiness and narcolepsy). The company has recently expanded its team to support the growing AUVELITY sales and has begun launching the new indication for agitation associated with Alzheimer's disease. These developments mark important near-term catalysts as Axsome continues to build momentum in its commercial operations.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Macy's will report its Q2 fiscal 2026 earnings on September 10, with analysts expecting adjusted EPS of $0.37 and net sales of $4.81 billion, both above company guidance. The retailer's turnaround strategy focuses on strengthening its core stores, gr...
Wells Fargo lowered its price target for Casey's General Stores to $750 from $960 after the company reported a 3.2% same-store sales growth in Q1, missing analyst expectations. Despite the sales miss, Casey's posted revenue of $5.68 billion and EPS o...
